Barrick Mining Corporation (B)vsGlaxoSmithKline PLC ADR (GSK)
B
Barrick Mining Corporation
$37.69
+1.48%
BASIC MATERIALS · Cap: $62.59B
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 93% more annual revenue ($32.67B vs $16.96B). B leads profitability with a 29.4% profit margin vs 17.5%. GSK appears more attractively valued with a PEG of 0.50. B earns a higher WallStSmart Score of 81/100 (A-).
B
Exceptional Buy81
out of 100
Grade: A-
GSK
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.3%
Fair Value
$137.12
Current Price
$37.69
$99.43 discount
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 52.6%
Revenue surging 64.5% year-over-year
Earnings expanding 150.0% YoY
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Keeps 29 of every $100 in revenue as profit
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : B
The strongest argument for B centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 52.6%. Revenue growth of 64.5% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : B
The primary concerns for B are PEG Ratio.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
B profiles as a growth stock while GSK is a mature play — different risk/reward profiles.
B carries more volatility with a beta of 1.00 — expect wider price swings.
B is growing revenue faster at 64.5% — sustainability is the question.
GSK generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
B scores higher overall (81/100 vs 70/100), backed by strong 29.4% margins and 64.5% revenue growth. GSK offers better value entry with a 66.0% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Barrick Mining Corporation
BASIC MATERIALS · GOLD · USA
Barnes Group Inc. provides engineering products, industrial technologies, and solutions in the United States and internationally. The company is headquartered in Bristol, Connecticut.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other GOLD Stocks
Want to dig deeper into these stocks?